Serum C-reactive protein to albumin ratio as a novel inflammation biomarker in psoriasis patients treated with adalimumab, ustekinumab, infliximab, and secukinumab: a retrospective study
Croatian Medical Journal · 2020-08 · 61 (4) · 333-337
DOI: 10.3325/cmj.2020.61.333 ↗Kurz gefasst
Fachartikel in der Zeitschrift Croatian Medical Journal, 2020-08. Verfasst von Funda Tamer und 1 weiteren Autor:innen. Die Arbeit wurde bisher 6-mal zitiert (Crossref).
Abstract (Originalsprache)
AIM: To assess C-reactive protein to albumin ratio (CAR) before and after treatment with biological agents in patients with psoriasis to determine whether CAR can be used as an inflammation biomarker. METHODS: Medical records of patients with psoriasis treated with biological agents at the Department of Dermatology, Gazi University Hospital were retrospectively evaluated between June 2018 and August 2019. The patients were divided into four groups based on the type of treatment (adalimumab, ustekinumab, infliximab, secukinumab). CAR was evaluated before and three months after treatment. RESULTS: The study enrolled 157 patients with psoriasis vulgaris (91 male) aged between 18 and 85. CAR significantly decreased in all treatment groups (adalimumab group P
Zitieren
APA
Tamer, F., & Avcı, E. (2020). Serum C-reactive protein to albumin ratio as a novel inflammation biomarker in psoriasis patients treated with adalimumab, ustekinumab, infliximab, and secukinumab: a retrospective study. Croatian Medical Journal, 61(4), 333-337. https://doi.org/10.3325/cmj.2020.61.333
Vancouver
Tamer F, Avcı E. Serum C-reactive protein to albumin ratio as a novel inflammation biomarker in psoriasis patients treated with adalimumab, ustekinumab, infliximab, and secukinumab: a retrospective study. Croatian Medical Journal. 2020;61(4):333-337. doi:10.3325/cmj.2020.61.333
BibTeX
@article{Tamer2020,
author = {Tamer, Funda and Avcı, Emine},
title = {Serum C-reactive protein to albumin ratio as a novel inflammation biomarker in psoriasis patients treated with adalimumab, ustekinumab, infliximab, and secukinumab: a retrospective study},
journal = {Croatian Medical Journal},
year = {2020},
volume = {61},
number = {4},
pages = {333--337},
doi = {10.3325/cmj.2020.61.333}
}
EUVIMED